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Abstract: This article reviews the literature on management of chronic cyclical pelvic pain 
(CCPP). Electronic resources including Medline, PubMed, CINAHL, The Cochrane Library, 
Current Contents, and EMBASE were searched using MeSH terms including all   subheadings 
and keywords: “cyclical pelvic pain”, “chronic pain”, “dysmenorrheal”, “nonmenstrual   pelvic 
pain”, and “endometriosis”. There is a dearth of high-quality evidence for this common 
  problem. Chronic pelvic pain affects 4%–25% of women of reproductive age. Dysmenorrhea 
of varying degree affects 60% of women. Endometriosis is the commonest pathologic cause of 
CCPP. Other   gynecological causes are adenomyosis, uterine fibroids, and pelvic floor myalgia, 
although other systems disease such as irritable bowel syndrome or interstitial cystitis may 
be responsible.   Management options range from simple to invasive, where simple medical 
  treatment such as the combined oral contraceptive pill may be used as a first-line treatment 
prior to invasive   management. This review outlines an approach to patients with CCPP through 
history, physical examination, and investigation to identify the cause(s) of the pain and its 
optimal management.
Keywords: cyclical pelvic pain, chronic pain, dysmenorrhea, nonmenstrual pelvic pain, 
endometriosis
Introduction
Chronic pelvic pain is defined as pelvic pain occurring for at least 6 months with 
  sufficient intensity to interrupt normal activities of daily life and requiring medical 
or surgical treatment. Chronic cyclic pelvic pain (CCPP) is traditionally considered 
as a subset of chronic pelvic pain that occurs in relation to the menstrual cycle.1  However, 
CCPP also incorporates pelvic pain that occurs with a cyclic pattern, which may not 
be related to the menstrual cycle. For example, pelvic pain that occurs at the time of 
  intercourse may give rise to a pattern of pain, which can be due to nonhormonal causes 
such as pelvic floor myalgia, provoked vestibulodynia, or pudendal neuralgia (PN). Other 
events can be responsible for CCPP such as ovulation giving rise to   Mittelschmerz pain. 
Although pain occurring with interstitial cystitis (IC) or irritable bowel syndrome (IBS) 
occurs without a particular pattern, patients may present with CCPP as this pain can be 
exacerbated by menstruation. Gynecologists need to be aware of a range of differential 
diagnoses for the optimal management of patients with CCPP.
Methods
This review was produced by searching the electronic resources including Medline, 
PubMed, CINAHL, The Cochrane Library (including the Cochrane Database of International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
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  Systematic Reviews), Current Contents, and EMBASE. 
The MeSH terms included all subheadings and keywords: 
“cyclical pelvic pain”, “chronic pain”, “dysmenorrhea”, 
“nonmenstrual pelvic pain”, and “endometriosis”.
Epidemiology
The exact epidemiology of CCPP is difficult to determine 
and there is paucity of data in this subset area of pelvic pain. 
Estimates from the reported prevalence of chronic pelvic 
pain which ranges from 4% to 25%2–4 and endometriosis, the 
most common gynecologic pathology causing chronic pelvic 
pain of 1%–7%5,6 would suggest that between 5%–10% of 
women may be affected. Primary dysmenorrhea of varying 
degree is reported to affect 60% of adult women7 and 72% 
of adolescents,8 with 12%–14% adults and 17% adolescents 
describing this as severe.9
Etiology
A large proportion of CCPP is due to hormonally driven 
pathology where the pain cycle is synchronous with the 
menstrual cycle. Although physiological causes including 
Mittelschmerz pain and primary dysmenorrhea are the most 
common cause of CCPP, these are typically mild. The most 
common gynecological pathology responsible for CCPP 
is endometriosis.1 Adenomyosis and fibroids can also give 
rise to CCPP, whereas cervical stenosis or an obstructive 
abnormality is a less common cause.
Other pelvic organs, including the gastrointestinal tract 
or urinary tract can be a source of cyclical pelvic pain, as 
well as the musculoskeletal or neurological system. There 
is an overlap between pelvic organs and muscles that share 
the same nerve supply, and a variety of contributing causes 
may coexist.10 Possible etiologies of chronic pelvic pain 
are listed in Table 1, and are discussed individually in the 
systems review.
A pragmatic approach to women 
with chronic cyclical pelvic pain
History
The most important part of the assessment for CCPP is 
accurate and meticulous history taking. A detailed, chrono-
logical history of pain must be obtained. This should include 
timing, onset and nature of pain, as well as its location, 
radiation, precipitating and relieving factors. Associated 
symptoms denoting the gastrointestinal system, urinary 
tract, musculoskeletal system should be elicited. Specific 
questions about pain during urination or defecation will aid 
in the management of CCPP. History should include results 
of previous investigation and treatments, both successful and 
unsuccessful. Current impact of pain on the patient’s quality 
of life, and the amount of medication used can be used as 
indicators of response to treatment.
Menstrual and obstetric background is an essential part 
of the history, with particular attention to cycles of pain in 
relation to menstruation. Onset of associated symptoms, such 
as dysuria or change of bowel habit in relation to menstrual 
cycle should be noted. A history of previous trauma such as 
instrumental delivery or episiotomy should be elicited. Desire 
for future fertility is crucial, as it will determine feasible 
treatment options. Sexual history may reveal the presence 
of deep dyspareunia and determine risk factors for pelvic 
inflammatory disease (PID).
A history of depression and other psychological disorders 
should be obtained. Although there is no definite causal rela-
tionship between depression and pelvic pain, the incidence of 
depression is higher in chronic pain patients.11 Patients with 
chronic pain also seem to have a higher incidence of previous 
physical or sexual abuse.12,13 Previous stressful experiences 
may have altered the neuropsychological process of perceiv-
ing pain, leading to excessive pain. Establishing trust and 
good rapport with the patient will help in identifying these 
issues. It may be best to leave this until a subsequent visit, 
rather than addressing it at the patient’s first visit.
Table 1 etiologies of chronic pelvic pain
Gynecological Physiologic 
  Primary dysmenorrheaa 
  Mittelschmerza 
Pathologic 
  endometriosisa 
  Adenomyosisa 
  Fibroid (uterine leiomyoma)a 
  Cervical stenosis or obstructive abnormalitya 
  Pelvic venous congestion syndromea 
  Ovarian remnant/residual ovary syndrome 
  Pelvic adhesions 
  Postpelvic inflammatory disease 
  endosalpingiosis
Gastrointestinal  
tract
Irritable bowel syndromea 
Inflammatory bowel disease 
Chronic constipation
Urinary tract Interstitial cystitis
Nervous system Pudendal neuralgia 
Provoked vestibulodynia
Muscloskeletal Pelvic floor myalgia 
Myofascial pain
Psychosocial Depression 
Physical/sexual abuse 
Drug seeking behavior
Note: aMay cause cyclic pelvic pain in relation to menstrual cycle.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Physical examination
The aim of the examination is to look for pathology, as well 
as to reproduce the patient’s usual pain to help identify the 
cause. Given the intermittent nature of pain in CCPP, it is best 
to examine the patient when she is in pain. For gynecologists 
seeing patients with chronic pelvic pain, it is important to 
examine the patient as a whole, rather than just examining 
the uterus and cervix.
General inspection of the patient during history taking 
should include general well being, posture, gait, and sco-
liosis. Such musculoskeletal abnormalities may predispose 
patients to chronic pain and alter their pain perception.14 Ask 
the patient to empty her bladder, and perform an urinalysis. 
Examination of the abdomen should take place with the 
patient supine, to inspect for scars, masses, and distension. 
Palpate for organomegaly, fecal loading, or other masses. 
Eliciting allodynia (vigorous pain response to light local-
ized pressure) may indicate psychologically driven pain 
or advanced chronic pain syndrome. The head raise test 
(Carnett’s test) is performed by asking the patient to lift their 
head whilst in the supine position. If pain is lessened by head 
raising then the pain is likely intraperitoneal as the rectus 
muscles protect the peritoneum from stretch. If, however, 
the pain is worsening by head raising then abdominal wall 
pathology is suspected.
The patient is then placed in lithotomy position and the 
vulva is inspected for irritation, inflammation, lesions, ulcers, 
or discharge. Particular attention should be given to vulvar 
vestibulitis, which is common in women with chronic pelvic 
pain. This condition can cause burning introital discomfort 
with intercourse. Perform a vaginal examination by inserting 
1 finger into the introitus and have the patient contract and 
relax her pelvic floor. This assesses tone and muscle control. 
The muscles of the pelvic floor and their attachments should 
be palpated with gentle compression, including puborectalis, 
pubococcygeus, coccygeus, piriformis, and obturator internus 
for tenderness and rigidity. They should not be tender and 
the patient should be able to contract and relax these muscles 
voluntarily. The ischial spine and Alcock’s canal are gently 
palpated bilaterally for tenderness and/or fibrosis, which may 
aid in diagnosis of PN.15
Palpate the anterior vaginal wall to locate tenderness 
along the urethra and bladder base. Tenderness may indicate 
possible lower urinary tract involvement. The cervix is gently 
palpated for motion tenderness. The posterior vaginal wall 
is palpated, especially looking for rectovaginal nodularity 
or localized tenderness which may be indicative of endo-
metriosis. A bimanual examination is performed, as gently 
as possible, to delineate the uterus and adnexa, looking for 
mobility,   tenderness, and masses. A tender uterus may reflect 
the   presence of   adenomyosis. A speculum examination is 
performed if swabs or a Pap smear is required, but a well 
performed digital examination is preferred, as it is less likely 
to provoke pain and muscle spasms after examination. Per 
rectal examination is reserved for cases where   compressing 
pathology is suspected or symptoms such as per rectal 
  bleeding are present.
Investigations
After obtaining a thorough history and physical examina-
tion, focused investigations need to be arranged, tailored to 
each patient depending on the information obtained from 
the history and examination. It should commence with those 
that are simple, inexpensive, and widely available, such as 
urinalysis, midstream urine specimen for microscopy, culture 
and sensitivity, vaginal swabs, and serological investigation 
such as full blood count, C-reactive protein, or CA 125.
Diagnostic imaging should be performed only when 
indicated by history and physical findings. Transvaginal 
and transabdominal ultrasound are valuable modality to 
evaluate the female genital tract, particularly when assessing 
structural abnormalities such as fibroids, adenomyosis, and 
adnexal pathology such as ovarian cysts or hydrosalpinges. 
It is effective in distinguishing cystic from solid lesions and 
allows information on vascular characteristics of the mass. 
Ultrasound is readily available, relatively inexpensive, and 
does not expose the patient to radiation. The ultrasound 
transducer can also identify points of maximal tenderness 
to aid in diagnosis of CCPP. However, in endometriosis, it is 
important to remember that pelvic ultrasound will only aid in 
determining the presence of deeply infiltrating endometriosis 
or involvement of the ovaries with the presence of an endo-
metrioma, which accounts for less than 20% of patients with 
endometriosis. Ultrasound is not helpful in diagnosing small 
volume peritoneal disease.16
Computed tomography has a limited role in imaging the 
female genital organs but can provide important information 
on involvement of the gastrointestinal tract,17 although tran-
srectal ultrasonography offers higher sensitivity for pathol-
ogy such as invasive rectovaginal endometriosis.18 Magnetic 
resonance imaging (MRI) is useful in characterizing pelvic 
masses as well as diagnosing adenomyosis, endometriomata, 
or deep endometriosis but its use is limited by high cost and 
varying availability.
Laparoscopy is indicated in patients with CCPP where a 
pelvic abnormality is suspected to find and treat   contributing International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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factors. Laparoscopy is the gold standard to diagnose   pathology 
such as endometriosis or adhesions. As all surgical investiga-
tions carry morbidity, thorough clinical assessment may lead 
to avoidance of unnecessary surgical procedures.
Systems review
The majority of CCPP is due to gynecological causes, which 
are frequently hormonally driven. However, any abdominal or 
pelvic structures may cause CCPP. The following is an outline 
of common conditions that may cause CCPP in different 
systems. It is important to remember that there is significant 
overlap and interaction between different systems and more 
than 1 diagnosis for the pain may be present.
Gynecologic causes
Primary dysmenorrhea
Primary dysmenorrhea refers to menstrual pain without 
pelvic pathology. This is the most common cause of CCPP 
in women of reproductive age, affecting 60% of women7 
and 72% of adolescents.8 It is often described as recurrent, 
crampy, colicky pain in the suprapubic region that occurs 
during menses associated with onset of menstrual flow with 
a typical duration of 2–3 days. It may be accompanied with 
nausea, fatigue, bloating and general malaise, and may radiate 
to the lower back and thighs.
Studies have shown that declining uterine progesterone 
levels in the late luteal phase during endometrial sloughing 
removes inhibition of arachidonic acid production, which is 
subsequently metabolized by the cyclooxygenase (COX)-2 
pathway into eicosanoids19,20 (including leukotrienes and 
prostanoids). These vasoactive eicosanoids cause abnormal 
uterine contractions leading to decreased uterine blood flow 
and subsequent ischemia, causing pain. This is supported 
by Doppler ultrasound studies showing high uterine artery 
resistance on the first day of menses in patients with primary 
dysmenorrhea compared with a control group.21 Dawood 
demonstrated that the intensity of menstrual cramps and 
associated symptoms of dysmenorrhea are directly propor-
tional to the amount of prostaglandins released in endometrial 
secretions,22,23 making excessive production of prostaglandins 
the problem rather than an increased sensitivity to the effect 
of prostaglandins. It has been suggested that vasopressin may 
also be involved in the etiology of primary dysmenorrhea, but 
its role remains controversial.24 How this would fit into thera-
peutic management is yet to be determined but may be in the 
form of additional analgesia for this particular problem.
The diagnosis of primary dysmenorrhea is made from a 
characteristic symptom history and the rapid improvement on 
appropriate therapy. As it is a diagnosis of exclusion, a detailed 
history and physical examination to look for   symptoms and 
signs indicative of pelvic pathology (such as endometriosis, 
adenomyosis, fibroid, PID, and pelvic adhesions) are required. 
Physical examination in patients with primary dysmenorrhea 
will be normal and laboratory tests, imaging studies, and 
laparoscopy are not mandatory to exclude these disorders, 
but should be performed as indicated, if pelvic disease is 
suspected.
Nonsteroidal anti-inflammatory drugs (NSAID) and the 
combined oral contraceptive pill (COCP) are the mainstay of 
treatment for primary dysmenorrhea. There is class I and II 
evidence that NSAID are an effective treatment for primary 
dysmenorrhea25–27 although this is insufficient to determine 
which individual NSAID is most effective and safe. The COCP 
is an effective treatment for primary dysmenorrhea28,29 in par-
ticular for women wishing to use hormonal contraception, 
although limited evidence is available on the efficacy of 
different preparations. It acts via suppressing ovulation and 
thinning the endometrium to reduce prostaglandin production, 
uterine blood flow, and cramps.
Mittelschmerz pain
“Mittelschmerz” (German for “middle pain”) refers to pelvic 
pain in ovulatory women that occurs in the middle of a men-
strual cycle. It is a sharp pelvic pain that may be felt low in the 
abdomen on either the right or left side. This pain is typically 
mild and unilateral, lasting for a few hours to few days, and is 
seldom severe enough to distress women. It is thought to be 
due to normal follicular enlargement just prior to ovulation, 
or to normal follicular rupture and the subsequent intraperi-
toneal spillage of follicular fluid and blood.30
endometriosis
Endometriosis is the most common gynecological   pathology 
causing CCPP accounting for 12%–32% of women of repro-
ductive age undergoing laparoscopy for pelvic pain, and for 
45%–70% in adolescents.31 Endometriosis is defined as the 
presence of endometrial glands and stroma outside of the 
endometrial cavity. Up to 75% of symptomatic   endometriosis 
causes cyclic pelvic pain with menstruation,32 though it 
is often associated with several different pain symptoms 
  including noncyclical, nonmenstrual pelvic pain.33–35 A range 
of other symptoms such as deep dyspareunia, dyschezia, 
subfertility, and abnormal menstrual bleeding may be 
present and may reflect the site and depth of endometriotic 
infiltration. In particular, deep dyspareunia and dyschezia 
are suggestive of posterior deep infiltrating endometriosis International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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at the rectovaginal septum.36 It is important to note that the 
severity of symptoms does not correlate with the severity of 
endometriosis.37
Physical examination in endometriosis is   important, as 
examination findings such as uterosacral nodularity or   palpable 
induration or tenderness in the posterior cul de sac or utero-
sacral ligaments may alter management. In advanced disease, 
lateral displacement of the cervix may be seen on speculum 
examination due to unilateral shortening of a diseased utero-
sacral ligament, or an ovarian endometrioma may be palpable 
during bimanual examination.
Laparoscopy and biopsy with histological findings of 
endometrial glands and stroma in the peritoneal tissues or 
other tissue biopsies is the gold standard in making the diag-
nosis of endometriosis.38 Although ultrasound is helpful in 
assessing the extent of disease by detecting endometriomas 
and deeply invasive uterosacral and rectal disease, it is not 
helpful in the diagnosis of small volume peritoneal disease.16 
Recent updates on nerve fibers in the endometrium of women 
with endometriosis may offer a new diagnostic investigation 
of endometriosis.39
In determining the treatment of endometriosis, the 
patient’s desire of future fertility, side effect profile, and 
personal preference needs to be accounted for. The best 
medical treatments for endometriosis include the COCP 
and progestins in their various forms since they may be 
used in the long term, have acceptable side effect profiles 
and are inexpensive. Other treatments including, andro-
genic agents such as danazol, and centrally acting drugs 
like gonadotrophin-releasing hormone (GnRH) analogs are 
limited by cost, duration of activity and more significant 
side effect profiles, without offering significantly greater 
benefits than the COCP.40 COCPs are effective41 but will 
of course prevent conception and may predispose to side 
effects such as migraine and thromboembolic disorders in 
some individuals. The use of the combined oral contraceptive 
on a continuous basis is effective in arresting menstruation, 
thus preventing dysmenorrhea. Progestogens have a variety 
of mechanisms of action including suppression of ovarian 
activity and have been demonstrated to be effective.42,43 The 
side effects may include irregular menstrual bleeding, weight 
gain, mood swings, and decreased libido. Androgenic agents 
that disrupt the menstrual cycle and often induce amenor-
rhea may be effective in endometriosis44 but the side effects 
such as acne, greasy skin, and deepening of the voice can 
be unacceptable to patients and occasionally irreversible. 
GnRH analogs can be used to suppress   ovarian function 
and will result in symptomatic relief of the pain symptoms 
of endometriosis45 but the side effects such as the develop-
ment of menopausal symptoms and the loss of bone mineral 
density limit its long-term use. Further development of new 
medical interventions such as Selective Estrogen Receptor 
Modulators, antiprogestogens, and antiangiogenic agents 
may provide further medical treatment options with fewer 
side effects in the future. Because of the chronic nature of 
endometriosis, medical treatment needs to be long term 
with low morbidity or side effects, making the COCP or 
progestogens the favored choice.
Surgical treatment of endometriosis aims to remove vis-
ible areas of endometriosis and restore anatomy by division of 
adhesions. This is the preferred option for those seeking fer-
tility or presenting with advanced disease with the presence 
of endometrioma or abnormal physical examination findings 
suggestive of deeply invasive endometriosis. Endometri-
omas are not amenable to medical treatment, and need to be 
removed surgically even if symptoms improve with medical 
treatment.46 Patients with deeply invasive disease in the rec-
tovaginal space and uterosacral ligaments benefit most with 
surgical excision, with reduction of dysmenorrhea, as well 
as dyspareunia and nonmenstrual pelvic pain.47–49 Regardless 
of the stage of endometriosis, randomized controlled trials 
comparing the effect of surgery to conservative management 
have shown that surgery and excision of endometriosis results 
in symptomatic improvement.32,50,51
Since Doyle52 described a technique to destroy the nerve 
pathways thought to be responsible for carrying pain fibers 
from the pelvis in 1955, surgical interruption of pelvic nerve 
pathways has been increasingly used for symptomatic treat-
ment of endometriosis. Laparoscopic uterine nerve ablation 
(LUNA) involves the transection of the uterosacral ligaments 
at their insertion into the cervix, where presacral neurectomy 
(PSN) involves the total removal of the presacral nerves lying 
within the boundaries of the interiliac triangle. Both procedures 
interrupt the majority of the cervical sensory nerve fibers thus 
diminishing uterine pain. Although observational studies have 
supported the use of both procedures53–55 results from random-
ized controlled trials demonstrate that the use of LUNA has no 
place in the management of chronic pelvic pain. Although PSN 
may be of benefit, it comes with the considerable risk of side 
effects including long-term bowel and bladder dysfunction and 
its use is recommended in patients who have been well counseled 
and it should be performed by experienced surgeons.50,56
Adenomyosis
Adenomyosis refers to a disorder in which endometrial glands 
and stroma are present within the uterine myometrium. It is International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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estimated to affect 20% of women of reproductive age, 
though the exact prevalence is unknown as only histological 
examination at hysterectomy makes the diagnosis definite.57 
Although menorrhagia is the most common presenting 
  symptom of adenomyosis, 25% of women present with cyclic 
pelvic pain with menstruation,57 where pain may be due to 
bleeding and swelling of endometrial islands confined by 
myometrium.
The ectopic endometrial tissue appears to induce hyper-
trophy and hyperplasia of the surrounding myometrium, 
which results in a diffusely enlarged uterus. Ultrasound 
is helpful in the diagnosis with a sensitivity of 65% and 
  specificity of 65%–98%.58,59 Although MRI has a higher 
sensitivity of 70% and specificity of 86%–98% for adeno-
myosis, cost and availability limits its use. Although   medical 
treatment with progestogens and the COCP may relieve 
dysmenorrhea and menorrhagia, symptoms usually reoccur 
with cessation of treatment, making hysterectomy the only 
definitive   treatment. Levonorgestrel-releasing intrauterine 
system have been shown to provide symptomatic relief 
up to 3 years60 and may offer an alternative to surgery. 
  Conservative surgery such as endometrial ablation or resec-
tion has been helpful in some patients, though follow-up has 
been limited to 3 years.61,62
Fibroid (uterine leiomyoma)
CCPP may be due to fibroids, frequently accompanied by 
menorrhagia. Uterine fibroids are the most common pelvic 
tumor in females, affecting 20%–40% of women of reproduc-
tive age.63 Although abnormal uterine bleeding is a common 
symptom from fibroids, cyclical pelvic pain may arise from 
uterine contraction and heavy menstrual flow. Fibroids may 
be responsible for deep dyspareunia, particularly anterior 
and fundal fibroids.64
Clinical diagnosis is often possible with ultrasound being 
the investigation of choice to confirm the clinical findings.65 
Treatment needs to be tailored to the individual patient 
depending on the symptoms, size and location of fibroids, and 
desire for future fertility. Medical treatments include COCPs, 
progestogens, levonorgestrel-releasing intrauterine system, or 
GnRH analogs, though long-term failure rates are high.66 Con-
servative surgical treatments for women who want to retain 
their fertility offer a viable alternative to hysterectomy and 
the route is dependent on the location and size of the fibroid 
with hysteroscopic resection of submucous fibroids being the 
treatment of choice for smaller lesions and laparoscopy and 
laparotomy being alternatives for lesions located elsewhere 
in the uterus, dependent on surgical skills. Hysterectomy 
is a definitive surgery, whereas uterine artery embolization 
and surgical uterine artery ligation are   alternative treatment 
options.
Cervical stenosis, intrauterine  
adhesions, and congenital obstructive 
Mullerian abnormality
Cervical stenosis from previous surgery (including dilatation 
and curettage, large loop excision of the transformation zone, 
or cone biopsy) or tumor (endometrial or cervical cancer) can 
be a cause of CCPP. New onset dysmenorrhea after   cervical 
procedures strongly suggests that cervical stenosis has 
developed and warrants thorough physical examination and 
dilatation of the cervix to allow access to, and drainage from 
the uterine cavity. Pending patient comfort can be performed 
as an outpatient procedure with dilators, or hysteroscopy or 
an ultrasound-guided procedure under general anesthesia. 
Alternative treatment options such as hysteroscopic   resection 
of endocervical tissue67 or laser vaporization68 have been 
described.
Pelvic pain from intrauterine adhesions (Asherman syn-
drome) is commonly cyclic and associated with menstrual 
dysfunction. Pain is usually associated with decreased or 
absent menstrual flow, the mechanism may be due to outflow 
obstruction with backflow into the fallopian tubes, creating 
a hematosalpinx and retrograde menstruation, or as a result 
of pockets of residual endometrium responding to hormonal 
stimuli, with no route for egress.69 Hysteroscopy is the gold 
standard for diagnosis of intrauterine adhesions.70,71
Townsend et al72 first described postablation tubal ster-
ilization syndrome (PATSS), which may be responsible 
for a new onset of CCPP. It occurs after total endometrial 
ablation from intrauterine contracture that forms from the 
collapsing of intrauterine walls after removal of distension 
medium, where persisting endometrium in cornua can cause 
symptomatic cornual hematometra (CH) or retrograde men-
struation, which in patients who have had tubal ligation can 
cause painful distension of the proximal tube. Retrospective 
studies have demonstrated the incidence of CH or PATSS 
may occur in up to 10% of patients who undergo endome-
trial ablation, requiring salpingectomy or hysterectomy as a 
treatment;73 however, this is likely to be an overestimation 
due to selection bias when large-scale prospective studies of 
endometrial ablation are considered.
Congenital anomalies of the female genital organs are 
rare causes of CCPP with the mechanism for pain often due 
to complete or total outlet obstruction. These problems pres-
ent in adolescents in conjunction with primary amenorrhea International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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or abnormal menstruation. Imperforate hymen, Mullerian 
anomalies such as vaginal agenesis in Mayer-Rokitansky-
Küster-Hauser syndrome, lateral fusion defects such as a 
rudimentary horn or vertical fusion defects such as cervical 
or vaginal agenesis can present with CCPP although pain can 
be noncyclical where there is persistent mechanical stretch 
on the tissues. A thorough history and physical examination 
looking for hematometra or hematocolpos, with pelvic ultra-
sound correlation is warranted. As renal anomalies are found 
in 20%–30% of women with Mullerian defects,74 radiological 
renal investigation such as renal ultrasound is indicated in 
all women with Mullerian defects.
Ovarian remnant and residual  
ovary syndrome
CCPP is a common presenting symptom from ovarian 
remnant or residual ovary syndrome. Ovarian remnant 
syndrome occurs in patients who have undergone bilateral 
oophorectomy with symptoms from the ovarian remnant, 
which was inadvertently left behind. Residual ovary syn-
drome occurs in patients whose ovaries were intentionally 
preserved at the time of surgery, who present subsequently 
with pathology. Patients often present with cyclic pelvic pain 
with mechanoreceptors often engaged due to the confined 
space of the entrapped tissue which may result in a mass that 
can be palpated or demonstrated on an ultrasound or other 
imaging technique. Of the patients who undergo hysterec-
tomy with conservation of ovaries for benign indications, 
2%–3% present with residual ovary syndrome requiring 
further operation, where most pain can be attributed to 
functional cysts and benign tumors. Malignant tumors of 
the ovary may be responsible in 12% of cases.75
Pelvic venous congestion syndrome
Pelvic venous congestion, a controversial entity, has also 
been proposed as a cause of pelvic pain with menstrual 
exacerbation.76 It refers to a condition in which characteristic 
symptoms of shifting location of pain, deep dyspareunia, and 
exacerbation of pain after prolonged standing occur. These 
symptoms are associated with radiological findings of pelvic 
varicosities that display reduced blood flow, though dilated 
ovarian veins are frequently seen on imaging in asymptomatic 
parous women.77
Other gynecological causes
Pelvic adhesions, chronic PID, and endosalpingiosis will 
usually cause more persistent chronic than cyclic pain, 
and these conditions are not responsive to hormonal 
treatments. Despite the common attribution of unilateral 
pelvic pain to an ovarian cyst, ovarian cysts do not usually 
cause pain,78 unless complicated by hemorrhage, rupture, 
or torsion.
Pelvic adhesions can be the result of previous surgery, 
infection, inflammation (endometriosis), or assisted reproduc-
tive technology procedures. An ongoing debate continues as 
to the cause of the pain in the presence of adhesions. In spite 
of several studies, correlation between pelvic pain and adhe-
sions still remains uncertain. For patients in this category, a 
multidisciplinary team approach is frequently required. PID 
can be complicated by chronic pelvic pain in 18%–33% of 
women regardless of the mode of antibiotic therapy.79,80 The 
exact mechanism of post-PID chronic pain is unknown, 
although it is thought to be from pelvic adhesions or neurologi-
cal priming. Endosalpingiosis is the finding of ciliated tubal 
epithelium outside of the fallopian tubes. Once the diagnosis 
is histologically confirmed, management is symptomatic, and 
medical or surgical treatments are often ineffective.81
Gastrointestinal tract
Irritable bowel syndrome
IBS, which affects 10%–20% of adults in developed 
countries,82–84 is a functional gastrointestinal disorder char-
acterized by abdominal pain and bowel symptoms such as 
bloating, urgency, diarrhea, and constipation. Cross-sectional 
studies have shown that approximately one-third of women 
with chronic pelvic pain have IBS.85,86 IBS is most preva-
lent during menstruating years and is exacerbated during 
menstruation,87,88 hence presenting with a cyclical pattern of 
pain, accompanied with dyspareunia and dysmenorrhea.89,90 
Colonoscopy should be considered in high-risk patients to 
exclude other pathology such as malignancy or inflammatory 
bowel disease.91,92 Treatment involves dietary manipulation 
and antispasmodic agents with fiber supplementation to 
relieve symptoms.93,94
Patients with inflammatory bowel disease present with 
intermittent crampy abdominal pain along with fatigue, 
diarrhea, weight loss, and/or rectal bleeding, and   appropriate 
endoscopy with biopsy is required to make a diagnosis. 
Although chronic constipation is common in women, chronic 
cyclic pain from constipation is not a common symptom.95
The urinary tract
Interstitial cystitis
IC is a noninfectious chronic inflammatory condition of the 
bladder, where the etiology and pathophysiology are poorly 
understood. IC can present as CCPP with associated urinary International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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symptoms (frequency, dysuria, urgency, or nocturia) that 
can fluctuate during the menstrual cycle with premenstrual 
flare,96–98 or worsen during or after intercourse.96 There is a 
large overlap between IC and chronic pelvic pain, as demon-
strated by a prospective multicenter trial showing 84% of 
women with chronic pelvic pain having urological symptoms 
consistent with IC.99 This condition has been reported to 
commonly coexist with endometriosis and may make the 
diagnosis of either more difficult.100
Urinalysis and a midstream urine sample should be 
obtained to exclude infection. Cystoscopy with hydrodis-
tention of the bladder may aid in diagnosis, demonstrating 
glomerulation and submucosal hemorrhage, as well as being 
therapeutic, giving symptomatic relief in 20%–30% for 
several months.101 A potassium sensitivity test where the 
bladder is filled with potassium chloride solution, leading to 
more pain when compared with saline, is not recommended 
for routine use, due to low specificity.102 Although there is 
no curative therapy, management should include simple 
analgesics, bladder retraining together with physiotherapy, 
and dietary modification to exclude acidic foods. Other 
medical   treatments include antihistamines, azathioprine, cor-
ticosteroids, and heparin. A small prospective study looking 
at a subgroup of women with CCPP and IC with negative 
laparoscopy for endometriosis, demonstrated symptomatic 
improvement in 83% women when treated with the oral 
contraceptive pill.98
Musculoskeletal system
Pelvic pain can arise from muscles of the pelvic floor as 
well as muscles of the abdominal wall, back, hips, and upper 
thighs. There is increasing recognition that spasms of these 
muscles can be primary or secondary causes of pelvic pain. 
Up to 85% of patients with chronic pelvic pain have muscu-
loskeletal dysfunction such as muscular spasm of the pelvic 
floor103,104 or postural changes such as scoliosis and pelvic 
rotation.105 Abnormal postures from such musculoskeletal 
dysfunction increase muscular tensions and spasm with 
consequent muscle shortening which then exacerbates or pro-
longs pain. Although it causes more constant pelvic pain than 
cyclic pain, it is important to consider musculoskeletal pain 
as a possible etiology for chronic pelvic pain and examine for 
posture, scoliosis, pelvic asymmetry, as well as performing 
vaginal examination of the pelvic floor muscles.
Pelvic floor myalgia is usually associated with   involuntary 
spasm of the pelvic floor muscles. This pain can be either con-
tinuous or episodic and may manifest as a sense of   aching, 
heaviness, or burning.106 It is not associated with the menstrual 
cycle, although the pain may be exacerbated by menses.107 
Sometimes sexual intercourse or certain activities can be the 
trigger for a flare. Since dyspareunia is the most common 
symptom of this problem, a pattern of pain with intercourse 
should be sought, and hence it can be considered as a cyclic 
cause of pain.
Manual therapy by experienced physiotherapists is the 
best treatment for women affected and involves a personal-
ized program of stretching, direct digital compression, and 
relaxation of affected muscles. In refractory cases, injection 
of botulinum toxin type A into pelvic floor muscles may be 
useful in reducing pelvic floor spasm and pelvic pain.108,109
Neurological
Patients with PN present with severe sharp pain along with 
the anatomical territory of the pudendal nerve (vagina, vulva, 
labia, perineum, and anorectal region). As pain is aggravated 
by intercourse, the patient may present with a distinct pat-
tern of pain, with dyspareunia and vulvar pain.110 It is also 
precipitated by prolonged sitting, and relieved by standing. 
The pathophysiology of PN is not clear, but is believed that 
a neuronal insult from stretching and compression is a sig-
nificant contributor. A multidisciplinary working party has 
described clinical diagnostic criteria for PN in 2006 (Nantes 
criteria111), where the 5 essential diagnostic criteria are: 
(1) pain along the anatomical distribution of the pudendal 
nerve; (2) the pain is aggravated by sitting; (3) the patient is 
not awakened at night by the pain; (4) there is no   objective 
  sensory loss on clinical examination; and (5) the pain is 
improved by an anesthetic pudendal nerve block. Treatment 
options range from conservative physical therapy to nerve 
blockade, surgical decompression and neuromodulation, 
though there are very few randomized controlled trials on 
efficacies for treatment techniques for PN.
Provoked vestibulodynia is a pain in the vaginal vestibule 
evoked by any kind of stimulation such as intercourse and 
light touch. It is reported to affect up to 12%–15% of women 
of reproductive age at some time of their life.112,113 It is one of 
the diagnoses under the umbrella of “vulvodynia” – a group 
of problems, rather than a specific diagnostic category. As the 
most common cause of dyspareunia,114,115 provoked vestibu-
lodynia can present with a nonmenstrual pattern of pelvic 
pain. It may result from intraepithelial neural hyperplasia 
that leads to nociception in this area, though the pathophysi-
ology remains poorly understood.116,117 Treatment options 
include physiotherapy with biofeedback, medical treatment 
with tricyclic antidepressants, topical anesthetics, local 
steroid injections, and vestibulectomy. Although randomized International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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controlled trials and prospective trials showing vestibulectomy 
is more effective than behavioral treatment,118,119 due to its 
  invasiveness and risk of worsening or reoccurrence of pain, 
surgery needs to be carefully considered.
Psychosocial
Although physical or sexual abuse is a rare cause of pelvic 
pain, it often makes it more difficult for the women to deal 
with pelvic pain, which may be reflected as CCPP. Untreated 
or unresolved abuse may interfere with the patient’s ability 
to cope with pain, and needs to be addressed appropriately. 
Depression is the most common emotional consequences of 
chronic pain and may become an obstacle to treat the actual 
pathology if left undiagnosed. Counseling and cognitive 
behavioral therapy by an appropriate health care professional, 
together with medical management of CCPP, may be the most 
effective treatment in affected women.
Management
Management of CCPP need to be tailored to the specific cause 
identified through history, examination and investigation, as 
well as the severity of pain and the patient’s desire for fertil-
ity. It is possible to undertake management without a specific 
diagnosis, such as with NSAID and COCP in patients not 
wishing an invasive management, and this approach may also 
be cost effective. The evidence of management of chronic pain 
in general is poor with studies usually including small numbers 
with limited follow-up of 6 months to a maximum of 5 years. 
Given that the nature of CPPP may last for decades, guide-
lines rather than solid evidence must prevail for management. 
Table 2 lists RCT’s of management strategies for chronic pain 
and it is apparent that there are very few Class 1 studies in this 
area, given how commonplace the condition is.
Given this information, Figure 1 proposes a pragmatic 
management approach for the optimal management of 
CCPP in premenopausal women. This flow chart should be 
considered as a guide only, as other variables such as the 
patient’s age and treatment preference or previous surgery 
may influence the choice of managements. There is a pau-
city of randomized controlled trials comparing therapeutic 
options for optimal management of CCPP, whereas stronger 
evidences are available for endometriosis-associated CCPP. 
Figure 1 is derived based on these randomized controlled 
trials, which are shown in Table 2.
If abnormal findings are detected at physical examination, 
such as rectovaginal nodularity or uterosacral thickening or 
ultrasonic demonstration of endometrioma raise a suspicion 
of advanced endometriosis, surgical management may be 
considered as a first-line treatment. If fertility is also an 
issue, then medical options with hormonal treatments are 
contraindicated and only surgery or assisted reproduction 
can be implemented. If the patient prefers noninvasive 
management, medical treatment can be offered with surgery 
considered if pain persists.
When there is no palpable disease and no demonstrable 
sonographic abnormalities, medical treatment should be con-
sidered first line, if the patient is willing. Since the majority of 
causes are hormonally driven gynecological causes, empiric 
treatment with the combined oral contraceptive is appropri-
ate in women with a normal physical examination who do 
not want to conceive, if there are no contraindications to the 
COCP. A trial of a monophasic preparation with a monthly 
cycle for 3 months is preferred. If there is good symptom 
relief from this, patients are advised to go on to a continuous 
regime for 2 months where the active pill is continuously 
taken followed by a withdrawal bleed. If this is well toler-
ated without a withdrawal bleed, the length of cycle can be 
extended to an indefinite time tailored to symptoms such as 
break through bleeding. Simple analgesics such as NSAID 
or paracetamol/acetaminophen should be commenced as 
first-line analgesia in conjunction with the oral contraceptive 
pill. Continuous progestogens such as medroxyprogesterone 
acetate, norethindrone acetate, or the levonorgestrel-releasing 
intrauterine system can be used as second-line medical 
treatment, with their efficacy demonstrated in randomized 
controlled trials for a variety of pelvic pain symptoms.120,121 
GnRH analogs have a very limited role in the management 
of CCPP, due to their side effects of loss of bone mineral 
density and development of menopausal symptoms limiting 
long-term use.
Long-term opioid therapy should be reserved for patients 
with severe cases, not responding to simple analgesia and 
hormonal medication, due to their side effects such as opioid 
bowel syndrome tolerance and dependence. Of note, improve-
ment in symptoms with medical treatment such as the COCP 
is not an absolute confirmation of a diagnosis since treatment 
effects are often not specific. As an example, hormonal treat-
ment of endometriosis may also improve pelvic congestion 
syndrome, IBS, or IC/painful bladder syndrome.97,122 If there 
is ongoing pain despite medical treatment or the patient 
develops intolerable side effects from treatment, surgery 
should be considered to provide diagnosis and treatment. 
Neuromodulators such as amitriptyline and gabapentin may 
also be considered in conjunction with a pain specialist with 
frequent patient review. Side effects of these medications are 
important to recognize.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Table 2 Randomized controlled trials comparing therapeutic options for CCPP
RCT Intervention Result and efficacy Side effects
Chronic pelvic pain with endometriosis
COCP vercellini et al125 Goserelin depot vs low-dose  
COCP for 6 months
Both groups had significantly reduced deep  
dyspareunia (goserelin superior with mean  
difference of 1.8; 95% CI, 0.1–3.5) and  
nonmenstrual pain (no difference) 
COCP group more effective at reducing  
dysmenorrhea (mean difference 4.3; 95% CI, 3.7–4.8)
Migraine  
Bloating  
Fluid retention  
venous thromboembolism
Harada et al126 Monophasic COCP vs  
placebo for 4 months
COCP group had significantly reduced verbal  
rating score for dysmenorrhea and volume of  
endometrioma on ultrasonography
GnRHa Rock et al45 Zoladex (goserelin  
acetate implant) vs danazol 
for 6 months
Zoladex is as effective as danazol in the  
treatment of endometriosis, 53% reduction in  
AFS endometriosis score with Zoladex vs  
46% with danazol
Hypoestrogenism  
(vasomotor symptoms, 
reduction in bone mineral  
density and osteoporosis)  
Cost
Gregoriou et al127 GnRHa alone vs GnRHa  
plus HRT for 6 months
Both groups equally effective in reducing pelvic  
pain with no difference of reduction of CPP in  
both group (P , 0.001) 
GnRH plus HRT group had significantly less 
hypoestrogenism side effects (P , 0.001)
LNG-IS Petta et al121 LNG-IS vs GnRHa for  
6 months
LNG-IS is as effective as GnRHa in  
treatment of endometriosis-associated  
CPP with no difference of reduction of CPP  
in both group (P . -0.999), without  
hypoestrogenic side effects of GnRHa
Spotting  
Breakthrough bleeding
Amenorrhea
Progestagens vercellini et al120 Depot medroxy  
progesterone acetate (MDA)  
vs OCOP + Danazol  
for 12 months
MDA group had reduced dysmenorrhea  
(mean difference vAS score 2.1; 95% CI, 0.8-3.4).  
Nonmenstrual pelvic pain and dyspareunia  
significantly decreased in both groups 
72.5% patients in MDA group was satisfied at  
1 year vs 57.5% in COCP + Danazol  
group (X  2 = 1.37, P = 0.24)
Amenorrhea 
Spotting, breakthrough 
bleeding 
Bloating
Breast tenderness  
Depression
Decreased libido
Surgery Sutton et al50 Laser ablation of  
endometriosis plus  
LUNA vs expectant 
management
62.5% of laser ablation and LUNA had improved  
pain vAS scores and 22.6% in expectant group  
at 6 months (z = 2.92, P , 0.01)
No operative or laser 
complications
Abbott et al33 Full excision of  
endometriosis vs  
diagnostic laparoscopy
Pain improved in 80% with immediate full  
excision vs 32% in diagnostic laparoscopy  
(X2 = 9.3, P = 0.002)
No difference in surgical 
morbidity in both groups
Wright et al128 excision vs ablation  
of endometriosis in  
mild endometriosis  
(rAFS classification 1-2)
Both excision and ablation reduced pain  
scores and pelvic tenderness 
No significant difference in the mean  
difference of pain scores presurgery  
and postsurgery (8.7 in ablation group  
and 11.2 in excision group, P = 0.57)
No difference in surgical 
morbidity in both groups
Jarell et al51 excision of endometriosis  
vs expectant management
Pain was significantly reduced at 1 year  
(P , 0.05), with no significant difference  
between both groups (45% in excision 
group and 33% in expectant management)
No difference in surgical 
morbidity in both groups
Chronic pelvic pain alone
COCP No RCT
LNG-IS No RCT
GnRHa Ling129 Depot Leuprolide vs  
placebo for 3 months
Depot Leuprolide group had reduced  
dysmenorrhea (pain score 1.0 vs 2.7, P , 0.001)  
and pelvic pain (pain score 1.9 vs 2.9, P , 0.001)
Hypoestrogenism  
(vasomotor symptoms,  
reduction in bone mineral  
density) 
Cost
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Consider other system 
Gastrointestinal 
Urinary tract 
Musculoskeletal 
Nervous system 
Psychosocial 
Simple hormonal
treatment 
COCP 
Progestogens 
Medical
management
Consider neuro-
modulators 
Amitriptyline 
Gabapentin 
Multidisciplinary team 
Gynecologist 
Physiotherapist 
Chronic pain specialist 
General practitioner 
Gastroenterologist 
Urologist 
Psychologist/psychiatrist
Refer and treat as
appropriate 
Analgesia 
Paracetamol/ 
acetaminophen 
NSAID 
Codeine 
No palpable disease 
No disease on ultrasound
Infertility 
Surgical 
management 
Ongoing pain 
Ongoing pain/ 
intolerable side
effects 
Consider surgery for
diagnosis & treatment
Palpable endometriosis 
or disease on ultrasound 
History 
Physical examination 
•
•
• ± Pelvic ultrasound 
Pt with CCPP 
•
•
•
•
•
•
•
•
•
•
•
•
•
•
• •
•
•
•
Figure 1 Flowchart describing a proposed management of chronic cyclic pelvic pain.
Table 2 (Continued)
RCT Intervention Result and efficacy Side effects
Pudendal  
nerve block
No RCT
Botulinum  
toxin type A
Abbott et al108 Bolulinum toxin type A vs  
placebo in patients with CPP  
and pelvic floor muscle spasm
Botulinum toxin A group had reduced  
dyspareunia (vAS score 66 vs 12,  
P , 0.001), nonmenstrual pelvic pain  
(vAS score 51 vs 22, P = 0.043) and pelvic  
floor pressure (49 vs 32, P , 0.001)
Cost 
vaginal bleeding  
from injection site
Adhesiolysis Keltz et al130 Right paracolic  
adhesiolysis vs no lysis
Patients undergone right paracolic  
adhesiolysis had greater pain reduction  
than those who did not (P = 0.014)
No difference in surgical  
morbidity in both groups
Abbreviations: COCP, combined oral contraceptive pill; CI, confidence interval; GnRHa, gonadotrophin-releasing hormone analog; LNG-IS, levonorgestrel-releasing 
intrauterine system; CPP, cyclical pelvic pain; LUNA, laparoscopic uterine nerve ablation. RCT, randomized controlled trials; HRT, hormone replacement therapy; vAS, visual 
analog scale; AFS, American Fertility Society.
In refractory CCPP, a combination of treatments is   usually 
required over time. The multifactorial nature of chronic   pelvic 
pain needs to be discussed with the patient and a good rap-
port as well as a partnership needs to be developed to plan a 
management program with regular follow-up. Promotion of 
a multidisciplinary approach in managing CCPP may expand 
treatment options,123 and create more realistic expectations 
of treatment outcomes. This will include the gynecologist, 
physiotherapist, general practitioner, chronic pain team with 
pain specialist, and pain psychologist. Repetitive surgery is International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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not optimal management and exposes the patient to significant 
risk of morbidity, without necessarily increasing the benefit of 
surgery.124 If the history and examination suggests that there 
is a nongynecological component to the pain, referral to the 
relevant health care professional such as a gastroenterologist 
or urologist needs to be considered.
Conclusion
CCPP is a common problem in women. Although most are 
due to gynecological causes, other systems such as gastro-
intestinal, urinary, muscular, and neurological systems may 
be involved. Thorough history and examination is the key 
to accurate diagnosis and successful management. Empiric 
treatment with the oral contraceptive pill with simple anal-
gesia is used as first line if there is no demonstrable disease 
on examination or pelvic ultrasound. Surgery is a preferred 
management for diagnosis and treatment if advanced 
endometriosis is suspected or fertility is to be retained. In 
refractory cases, the demands of wide ranging differential 
diagnoses and therapies may be met by a multidisciplinary 
approach with other health professionals.
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